Patent US4154820A successfully refreshed from Google Patents.
US4154820A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
Assignee: Akzona Inc
•
Filing: 1977-09-26
•
Granted: 1979-05-15
•
Expires: 1997-09-26
Abstract
Abstract A new and remarkably stable synthesized conjugated estrogen composition comprising one or more selected alkali metal synthetic conjugated estrogen sulfate salts and an effective amount of one or more suitable antioxidants has been found for use in novel and stable therapeutic preparations of a pH of not less than about 7 which are adapted to relieve, inter alia, complaints occurring in the menopausal syndrome and other female complaints. Preferably, the steroids are selected from the sodium and potassium salts of the group consisting of estrone, equilin, 17 alpha -dihydroequilin, and mixtures or conjugates thereof. Most preferably, the preparations are so formulated so that sodium estrone sulfate, sodium equilin sulphate, and 17 alpha -dihydroequilin sodium sulphate as conjugated estrogens are present in a weight ratio of about 6:3:1, respectively and administered in tablets containing 0.625 mg, 1.25 mg, or 2.5 mg of total conjugated estrogens.
Inventors
- 👤 Johan R. A. Simoons
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 05:24
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/06; A61K47/16; A61K47/18; A61K47/183; A61K31/00; A61K31/56; A61K31/565; A61K47/02; A61K47/20; A61K47/22
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
147 words
A stabilized therapeutic preparation exhibiting no oxidation and less than about 5% hydrolysis up to at least 24 months, said preparation adapted for treatment of menopausal syndrome, female hypogonadism, amenorrhea, female castration, primary ovarian failure, abnormal uterine bleeding due to hormonal imbalance, and senile vaginitis, consisting essentially of: at least one alkali metal sulfate salt of a synthetic conjugated estrogen selected from the group consisting of estrone, equilin, 17α-dihydroequilin, 17β-hydroequilin, 17β-estradiol, 17α-estradiol, equilenin, and 17β-dihydroequilenin in estrogenically effective proportions, and an antioxidant effective amount of at least one suitable antioxidant for said alkali metal sulfate salt of said synthetic conjugated estrogen selected from the group consisting of sodium sulfite, potassium sulfite, sodium metabisulfite, potassium metabisulfite, sodium bisulfite, potassium bisulfite, sodium thiosulfate, potassium thiosulfate, thioglycerol, thiosorbitol, cysteine hydrochloride, and α-tocopherol, wherein the preparation is maintained at an alkalinity corresponding to a pH of not less than about 7.0.
Claim 2
Dependent Claim
147 words
A stabilized therapeutic preparation exhibiting no oxidation and less than about 5% hydrolysis up to at least 24 months, said preparation adapted for treatment of menopausal syndrome, female hypogonadism, amenorrhea, female castration, primary ovarian failure, abnormal uterine bleeding due to hormonal imbalance, and senile vaginitis, consisting essentially of: at least one alkali metal sulfate salt of a synthetic conjugated estrogen selected from the group consisting of estrone, equilin, 17α-dihydroequilin, 17β-hydroequilin, 17β-estradiol, 17α-estradiol, equilenin, and 17β-dihydroequilenin in estrogenically effective proportions, and an antioxidant effective amount of at least one suitable antioxidant for said alkali metal sulfate salt of said synthetic conjugated estrogen selected from the group consisting of sodium sulfite, potassium sulfite, sodium metabisulfite, potassium metabisulfite, sodium bisulfite, potassium bisulfite, sodium thiosulfate, potassium thiosulfate, thioglycerol, thiosorbitol, cysteine hydrochloride, and α-tocopherol, wherein the preparation is maintained at an alkalinity corresponding to a pH of not less than about 7.0.
Claim 3
Dependent Claim
31 words
The preparation of claim 1 in unit dosage form to treat abnormal uterine bleeding or discomfort in menopausal syndrome containing between about 5 and about 25 mg. of synthetic conjugated estrogen.
Claim 4
Dependent Claim
34 words
The pharmaceutical composition of claim 1, wherein said antioxidant is present in an amount of from about 2.5 to about 6 moles of antioxidant per mole of alkali metal salt of synthetic conjugated estrogens.
Claim 5
Dependent Claim
15 words
The preparation of claim 1 wherein the alkali metal is selected from sodium and potassium.
Claim 6
Dependent Claim
21 words
The preparation of claim 4, wherein the antioxidants are selected from the group consisting of sodium sulfite, potassium sulfite, and dlα-tocopherol.
Claim 7
Dependent Claim
19 words
The preparation of claim 4, wherein the pH is maintained at an alkalinity of about 7.0 to about 8.5.
Claim 8
Dependent Claim
37 words
The preparation of claim 4, wherein the conjugated estrogens comprise a mixture of sodium estrone sulfate, sodium equilin sulfate, and 17α-dihydroequilin sodium sulfate which are present in a weight ratio to each other of about 6:3:1, respectively.
Claim 9
Dependent Claim
29 words
The preparation of claim 4 in unit dosage adapted for oral administration to treat discomfort in menopausal syndrome, containing about 0.2 to about 20 mg. of synthetic conjugated estrogens.
Claim 10
Dependent Claim
21 words
The preparation of claim 8, wherein the synthetic conjugated estrogens are present from about 0.3 to about 2.5 mg. per dose.
Claim 11
Independent Claim
158 words
A method for stabilizing therapeutic compositions that are adapted for treatment of menopausal syndrome, female hypogonadism, amenorrhea, female castration, primary ovarian failure, abnormal uterine bleeding due to hormonal imbalance, and senile vaginitis, and exhibiting no oxidation and less than about 5% hydrolysis for times greater up to at least 24 months, which compositions consist essentially of at least one alkali metal sulfate salt of a synthetic conjugated estrogen selected from the group consisting of estrone, equilin, 17α-dihydroequilin, 17β-hydroequilin, 17β-estradiol, 17α-estradiol, equilinen, and 17β-dihydroequilenin in estrogenically effective proportions, said method comprising: adding an antioxidant effective amount of at least one suitable antioxidant for said alkali metal sulfate salt of said synthetic confugated estrogen selected from the group consisting of sodium sulfite, potassium sulfite, sodium metabisulfite, potassium metabisulfite, sodium bisulfite, potassium bisulfite, sodium thiosulfate, potassium thiosulfate, thioglycerol, thiosorbitol, cysteine hydrochloride, and α-tocopherol, wherein the preparation is maintained at an alkalinity corresponding to a pH of not less than about 7.0.
Claim 12
Independent Claim
158 words
A method for stabilizing therapeutic compositions that are adapted for treatment of menopausal syndrome, female hypogonadism, amenorrhea, female castration, primary ovarian failure, abnormal uterine bleeding due to hormonal imbalance, and senile vaginitis, and exhibiting no oxidation and less than about 5% hydrolysis for times greater up to at least 24 months, which compositions consist essentially of at least one alkali metal sulfate salt of a synthetic conjugated estrogen selected from the group consisting of estrone, equilin, 17α-dihydroequilin, 17β-hydroequilin, 17β-estradiol, 17α-estradiol, equilinen, and 17β-dihydroequilenin in estrogenically effective proportions, said method comprising: adding an antioxidant effective amount of at least one suitable antioxidant for said alkali metal sulfate salt of said synthetic confugated estrogen selected from the group consisting of sodium sulfite, potassium sulfite, sodium metabisulfite, potassium metabisulfite, sodium bisulfite, potassium bisulfite, sodium thiosulfate, potassium thiosulfate, thioglycerol, thiosorbitol, cysteine hydrochloride, and α-tocopherol, wherein the preparation is maintained at an alkalinity corresponding to a pH of not less than about 7.0.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-05-14 | 1982-11-13 | 1983-05-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-05-14 | 1986-11-13 | 1987-05-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-05-14 | 1990-11-13 | 1991-05-15 | $7700.00 | Window Closed / Lapsed |